Clinical Trial

A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is a single arm, open label, dose exploring clinical trial to evaluate the safety, efficacy, cellular metabolic dynamics, and pharmacodynamics of ct1190b cells in relapsed / refractory B-cell acute lymphoblastic leukemia.
Trial Details
NCT Number NCT07470073
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions ALL (Acute B-Lymphoblastic Leukemia)
Enrollment 18 participants
Start Date 2026-04-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-13